Management of Intracerebral Hemorrhage With Aminocaproic Acid – Pilot Study

Overview

This is single-arm, open-label, safety and feasibility pilot study of ɛ-aminocaproic acid in ICH patients. Consecutive ICH volume with hematoma volume less than 30 mL by ABC/2 method presenting within 3 hours of symptom onset, meeting all inclusion criteria, and without exclusions will be consented and enrolled. Subjects will receive 5 grams of intravenous ɛ-aminocaproic acid over 1 hour, followed by the same at 1 mg/hour for 23 hours. Comupted tomography (CT) head will be done at 24 hours in order to follow hematoma size. Electrocardiogram, lower extremity venous Doppler and NIHSS will also be done at 24 hours. The patient will be followed in the clinic 30-90 days post discharge for functional status.

Full Title of Study: “A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2017

Interventions

  • Drug: ɛ-Aminocaproic Acid
    • Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset

Arms, Groups and Cohorts

  • Experimental: Treatment
    • Study drug

Clinical Trial Outcome Measures

Primary Measures

  • Hematoma volume
    • Time Frame: 24 hours
  • Lower extermity deep vein thrombosis on venous duplex ultrasound
    • Time Frame: 24-48 hours
  • Evidence of cardiac ischemia on the electrocardiogram
    • Time Frame: 24 hours
  • National Insitutes of Health Stroke Scale score
    • Time Frame: 24 hours

Secondary Measures

  • Modified Rankin Scale score
    • Time Frame: 30 Days

Participating in This Clinical Trial

Inclusion Criteria

1. Age 18-80 years 2. Supratentorial ICH ≤ 30 mL in volume and seen on ≥ 2 slices on a 0.5 mm CT head 3. IVH involving < 50% of the ipsilateral lateral ventricle will be allowed 4. Treatment initiated within 1 hour of baseline CT and 3 hours of onset or last known normal Exclusion Criteria:

1. Baseline mRS ≥ 2 2. Infratentorial hemorrhage (brainstem/cerebellum) 3. Any supratentorial hemorrhage extending to the brainstem 4. ICH > 30 mL 5. Patients who undergo surgical evacuation 6. Presenting outside of the 3 hour window 7. Intraventricular extension > 1/2 of one lateral ventricle 8. Intraventricular extension into the 3rd or 4th ventricle, or the aqueduct or involving >50% of the ipsilateral lateral ventricle 9. ICH due to trauma 10. ICH due to aneurysm of arteriovenous malformation 11. ICH due to underlying neoplasm or infectious mass 12. ICH due to Warfarin or other oral or intravenous anticoagulants 13. International normalization ratio > 1.4 14. Life expectancy < 1 year (prior to ICH onset); due to any cause. 15. History of recent ischemic stroke (within the past 3 months) 16. History of deep vein thrombosis or pulmonary embolism 17. History of recent myocardial infarction (within the past 3 months) 18. Known history of hypercoagulable state 19. History of cancer 20. Glomerular filtration rate < 60 mL/min 21. Received any hemostatic therapy for any indication (last 14 days) 22. Received any investigational therapy in last 90 days 23. "Do Not Resuscitate" order in place or expected, advance directives that could limit aggressive treatment measures.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The University of Texas Health Science Center at San Antonio
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Vivek Misra, MD, Study Chair, The University of Texas Health Science Center at San Antonio
    • Jean-Louis Caron, MD, FRCS(C), Study Director, The University of Texas Health Science Center at San Antonio
    • Reza Behrouz, DO, Principal Investigator, The University of Texas Health Science Center at San Antonio

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.